Recently, the Beijing Key Laboratory of Precision Diagnosis and Innovative Translational Research for Pediatric Rare Diseases (hereinafter referred to as "the Laboratory"), co-established with the par

The 3-month follow-up results of the first sentinel patient in the RDGT-101 clinical study (ChiCTR2600121466), led by Professor Feng Zhichun’s team at the Seventh Medical Center of Chinese PLA General Hospital, have been officially announced. This is the world’s first human clinical study of AAV9-NAGLU for mucopolysaccharidosis type IIIB (MPS IIIB) administered via intracerebroventricular (ICV) injection, marking landmark preliminary evidence for this innovative therapy.

Under the strategic cooperation framework between E-Town Holdings and Fangchenggang City, representatives from the biomedicine sectors of Beijing and Guangxi have carried out in-depth exchanges. As on

On the morning of May 14, US Eastern Time, at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Byongen Therapeutics delivered an oral presentation, disclosing for th

The 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2026) was grandly held in Boston, USA, from May 11 to 15 local time. Beijing Genecradle Therapeutics Co., Ltd. (herein

On March 16, 2026, GC801 injection, an IgG (immunoglobulin G) degrading enzyme drug independently developed by Beijing Genecradle Therapeutics Co., Ltd. received the implied clinical trial approval from the National Medical Products Administration (NMPA) (Application No.: CXSL2501108). The indication applied for in this submission is: pre-treatment AAV antibody depletion for type 2 spinal muscular atrophy (SMA) gene therapy. This marks the fifth Class 1 new drug and the eighth registered clinical trial submitted by Genecradle Therapeutics.

On December 26, 2025, the Phase I/II clinical trial launch meeting for GC310 adeno-associated virus (AAV) injection, an AAV gene therapy drug independently developed by Beijing Genecradle Therapeutics

On December 23, 2025, GC801 Injection, an IgG (Immunoglobulin G)-degrading enzyme drug independently developed by Beijing Genecradle Therapeutics Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics"), was accepted by the National Medical Products Administration (NMPA) for clinical trial registration review. Classified as a Class 1 Therapeutic Biological Product, this marks the fifth new drug clinical trial application submitted by Genecradle Therapeutics.

On November 10, 2025, GC101 Adeno-Associated Viral Vector Injection, a gene therapy agent for spinal muscular atrophy (SMA) independently developed by Beijing Genecradle Therapeutics Co., Ltd. (hereaf